sulfonylurea receptor Inhibitors
2 drugsAbout sulfonylurea receptor
The sulfonylurea receptor (SUR) is a protein complex that regulates insulin secretion. It is a key component in pancreatic beta cells, influencing glucose homeostasis. Its primary function involves modulating ATP-sensitive potassium channels.
SUR is a well-established drug target, particularly for metabolic disorders like diabetes. Currently, there is no genetic evidence available linking this target to specific diseases.
SUR is targeted by 2 FDA-approved small molecule drugs: GLYBURIDE AND METFORMIN HYDROCHLORIDE, and PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE. These drugs are marketed by HERITAGE and CHARTWELL RX, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Diabetes Mellitus Type 2 with only 5 trials.
Top sulfonylurea receptor Drugs
The competitive landscape includes HERITAGE and CHARTWELL RX, each with approved drugs.
The presence of only two companies suggests relatively low market competition and potential entry opportunities.
sulfonylurea receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets sulfonylurea receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
sulfonylurea receptor Clinical Trials 1,069 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 259 | 202 | 26 | 30 | 89% |
| Phase 2 | 299 | 169 | 80 | 49 | 68% |
| Phase 3 | 241 | 188 | 26 | 25 | 88% |
| Phase 4 | 270 | 196 | 38 | 35 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
sulfonylurea receptor Drug Approval Timeline (2013 - 2013)
The approval timeline spans 10 years, with the first drug approved in 2004 and the most recent in 2013.
The lack of recent approvals may indicate market saturation or challenges in developing new SUR-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 5 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 514 clinical trials targeting sulfonylurea receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities